The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

Makers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

The two longer-term headwinds facing GLP-1 drugs — Medicare negotiations going into effect in 2027 and the patent cliff for semaglutide in 2032 — are why the company has already started ...

Rybelsus (semaglutide) is a brand-name prescription ... If a person has an Original Medicare plan and Part D, they will pay a separate monthly premium for Part D in addition to their Part B ...

Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

And the inclusion of the semaglutide drugs — Wegovy for weight ... the biggest reason Novo isn't overly concerned is because Medicare is not its largest market in the US. Until the start of ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...